Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab + NB-UVB in Plaque Psoriasis
NCT00302445Phase 4Completed
- Sponsor
- DermResearch
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in plaque psoriasis, sponsored by DermResearch. Primary endpoint: Percent subjects who reach PASI 75 at 12 weeks. Started Mar 2006; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00302445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302445.